Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 27;5(1):vdad066. doi: 10.1093/noajnl/vdad066

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — The broader target specificity of WSD-0922 enhances efficacy in GBM39. (A) Volcano plots were generated to show the differential adaptive response of intracranial patient derived xenograft tumors to WSD-0922 and erlotinib. Data points represent the log₂ fold change (FC) of the average abundance in response to erlotinib over the WSD-0922 average abundance of a given phosphopeptide ( $\log_{2} (e r l o t i n i b / W S D - 0922)$ ). Dotted lines represent cutoffs for meaningful differences in abundance: log₂FC with an absolute value ≥ 0.585, and –log₁₀P-value ≥ 1.3. (B) STRING diagram of GBM39 phosphopeptides that had differential abundance in response to erlotinib and WSD-0922. Interactions with medium confidence from all interaction sources except “Textmining” are shown, and disconnected nodes were hidden for clarity. (C) Plots showing the abundances of select phosphopeptides from a subnetwork in B.